About us News Facilities People Research
 
 
 
 

S. Larry Goldenberg, M.D., FRCSC, FACS

Director, The Prostate Centre at VGH
Professor, Department of Surgery, UBC
Head, Division of Urology, UBC and VHHSC
Active Staff, Division of Urology, Vancouver General Hospital
Research Consultant, Department of Cancer Endocrinology, BCCA
Consultant Urologist, Department of Urology, University of Washington

Jack Bell Research Centre
2660 Oak St.
Vancouver, BC
Canada V6H 3Z6
Office: 604-875-5003
Fax: 604-875-5604
E-mail: lgold@interchange.ubc.ca

   

Research Interest

My research involves the study of diagnostics, education and novel treatment approaches of prostate cancer. In patients with early, localized tumours I have co-developed and tested clinical protocols in which neoadjuvant hormone therapy is administered prior to surgical removal of the prostate. I have been the co-principal investigator in 2 large, Canadian national trials testing either 3 or 8 month durations of therapy. This work is ongoing and attracting international curiosity.

For patients with more advanced cancer, continuous hormone therapy has been the mainstay form of treatment. Supported by experiments showing that intermittent androgen suppression (IAS) delays time to androgen-independent progression in our tumour model systems, I tested IAS in a group of patients with prostate cancer. Based on these preliminary results, additional Phase II and Phase III trials have begun across Canada (NCIC), the USA, and in Europe. I am the Canadian principal investigator of an international intergroup study of IAS in men with metastatic cancer.

I am leading an MR research team to investigate the role of imaging and spectroscopy in prostate cancer.

I am currently initiating research into the development of "point of care" diagnostic devices for "on the spot" PSA measurements.

I am proud of the publication of my book "Prostate Cancer: All you need to know to take an active part in your treatment" which is now in 3rd edition printing.

Paperback - 269 pages 3rd ed edition (January 2001)
Language: English
Intelligent Patient Guide (Intelligent patient guide) ; ISBN: 0969612559
   

Publications

Davison BJ, Parker PA, Goldenberg SL.. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int. 93 (1) : 47 - 51. 2004

Davison BJ, Goldenberg SL, Gleave ME, Degner LF. Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum. 30 (1) : 107 - 14. 2003

Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int. 91 (1) : 14 - 7. 2003

Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs 25 (1) : 42 - 49. 2002

July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (3) : 179 - 188. 2002

Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 24 (8) : 749 - 757. 2002

Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology 60 (3) : 45 - 51. 2002

Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 60 (3) : 52 - 6. 2002

   
   

© Copyright 2000- 2007 The Prostate Centre at Vancouver General Hospital | About this site
Any questions or comments on this page, please contact the webmaster.